Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

U Banerji; CML van Herpen; C Saura; F Thistiethwaite; S Lord; V Moreno; IR Macpherson; V Boni; C Rolfo; EGE de Vries; S Rottey; J Geenen; Ferry Eskens; M Gil-Martin; EC Mommers; NP Koper; P Aftimos

doi:10.1016/s1470-2045(19)30328-6

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

U Banerji, CML van Herpen, C Saura, F Thistiethwaite, S Lord, V Moreno, IR Macpherson, V Boni, C Rolfo, EGE de Vries, S Rottey, J Geenen, Ferry Eskens, M Gil-Martin, EC Mommers, NP Koper, P Aftimos

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

379 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1124-1135
Number of pages	12
Journal	Lancet Oncology
Volume	20
Issue number	8
DOIs	https://doi.org/10.1016/s1470-2045(19)30328-6
Publication status	Published - 2019

Research programs

EMC MM-03-86-08

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1470-2045(19)30328-6

http://hdl.handle.net/1765/118918

Cite this

Banerji, U., van Herpen, CML., Saura, C., Thistiethwaite, F., Lord, S., Moreno, V., Macpherson, IR., Boni, V., Rolfo, C., de Vries, EGE., Rottey, S., Geenen, J., Eskens, F., Gil-Martin, M., Mommers, EC., Koper, NP., & Aftimos, P. (2019). Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20(8), 1124-1135. https://doi.org/10.1016/s1470-2045(19)30328-6

@article{0b7b4a1566ae45928d17c0cf09ef96a8,

title = "Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study",

author = "U Banerji and {van Herpen}, CML and C Saura and F Thistiethwaite and S Lord and V Moreno and IR Macpherson and V Boni and C Rolfo and {de Vries}, EGE and S Rottey and J Geenen and Ferry Eskens and M Gil-Martin and EC Mommers and NP Koper and P Aftimos",

year = "2019",

doi = "10.1016/s1470-2045(19)30328-6",

language = "Undefined/Unknown",

volume = "20",

pages = "1124--1135",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

Banerji, U, van Herpen, CML, Saura, C, Thistiethwaite, F, Lord, S, Moreno, V, Macpherson, IR, Boni, V, Rolfo, C, de Vries, EGE, Rottey, S, Geenen, J, Eskens, F, Gil-Martin, M, Mommers, EC, Koper, NP & Aftimos, P 2019, 'Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study', Lancet Oncology, vol. 20, no. 8, pp. 1124-1135. https://doi.org/10.1016/s1470-2045(19)30328-6

TY - JOUR

T1 - Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

AU - Banerji, U

AU - van Herpen, CML

AU - Saura, C

AU - Thistiethwaite, F

AU - Lord, S

AU - Moreno, V

AU - Macpherson, IR

AU - Boni, V

AU - Rolfo, C

AU - de Vries, EGE

AU - Rottey, S

AU - Geenen, J

AU - Eskens, Ferry

AU - Gil-Martin, M

AU - Mommers, EC

AU - Koper, NP

AU - Aftimos, P

PY - 2019

Y1 - 2019

U2 - 10.1016/s1470-2045(19)30328-6

DO - 10.1016/s1470-2045(19)30328-6

M3 - Article

SN - 1470-2045

VL - 20

SP - 1124

EP - 1135

JO - Lancet Oncology

JF - Lancet Oncology

IS - 8

ER -